168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC).
Saved in:
| Title: | 168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC). |
|---|---|
| Authors: | Halmos, B.1 (AUTHOR), Cobb, P.2 (AUTHOR), Johnson, M.L.3 (AUTHOR), Jain, L.4 (AUTHOR), Kim, S.J.4 (AUTHOR), Saraf, S.4 (AUTHOR), Lala, M.4 (AUTHOR), Kurata, T.5 (AUTHOR) |
| Source: | Annals of Oncology. 2021 Supplement 7, Vol. 32, pS1456-S1456. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 153829471 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Halmos%2C+B%2E%22">Halmos, B.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cobb%2C+P%2E%22">Cobb, P.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Johnson%2C+M%2EL%2E%22">Johnson, M.L.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jain%2C+L%2E%22">Jain, L.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kim%2C+S%2EJ%2E%22">Kim, S.J.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Saraf%2C+S%2E%22">Saraf, S.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lala%2C+M%2E%22">Lala, M.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kurata%2C+T%2E%22">Kurata, T.</searchLink><relatesTo>5</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2021 Supplement 7, Vol. 32, pS1456-S1456. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=153829471 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2021.10.187 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S1456 Titles: – TitleFull: 168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Halmos, B. – PersonEntity: Name: NameFull: Cobb, P. – PersonEntity: Name: NameFull: Johnson, M.L. – PersonEntity: Name: NameFull: Jain, L. – PersonEntity: Name: NameFull: Kim, S.J. – PersonEntity: Name: NameFull: Saraf, S. – PersonEntity: Name: NameFull: Lala, M. – PersonEntity: Name: NameFull: Kurata, T. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 12 Text: 2021 Supplement 7 Type: published Y: 2021 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 32 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
